Insights

Sustainable Bioproduction Opportunity to position Alkion as a supplier of ultra-scalable, carbon-neutral plant-based APIs and complex extracts for pharmaceutical and agri-food partners, appealing to buyers prioritizing sustainability and cost efficiency.

Global Immunity Platform Leverage the QS program derived from Quillaja saponaria to explore partnerships for large-scale vaccine adjuvant production, targeting NGOs, public health agencies, and governments seeking affordable, diversified vaccine access.

Cannabinoid API Readiness Capitalize on the historic R&D licence for standardized cannabinoid production to offer regulated APIs and extracts for CNS therapies, attracting biotech and pharma firms seeking compliant, scalable cannabinoid solutions.

Industrial Bioproduction Highlight readiness to collaborate on industrial in-vitro bioproduction platforms with AI-robot automation, presenting a compelling case for pharma manufacturers and contract development organizations aiming to modernize production.

Agri-Food Profitability Target farmers and agribusiness partners with the biosynthesis lab’s healthy sweet protein, promoting revenue uplift through high-demand sugar alternatives and diversified product lines for food and pharmaceutical applications.

Similar companies to Alkion BioInnovations

Alkion BioInnovations Tech Stack

Alkion BioInnovations uses 8 technology products and services including WordPress, 1&1, Hammer.js, and more. Explore Alkion BioInnovations's tech stack below.

  • WordPress
    Content Management System
  • 1&1
    E-commerce
  • Hammer.js
    Javascript Libraries
  • Swiper
    Javascript Libraries
  • Modernizr
    Javascript Libraries
  • Leaflet
    Maps
  • IONOS
    Web Hosting
  • WPML
    Web Platform Extensions

Media & News

Alkion BioInnovations's Email Address Formats

Alkion BioInnovations uses at least 1 format(s):
Alkion BioInnovations Email FormatsExamplePercentage
First.Last@alkinnov.comJohn.Doe@alkinnov.com
93%
First.Middle@alkinnov.comJohn.Michael@alkinnov.com
7%

Frequently Asked Questions

What is Alkion BioInnovations's official website and social media links?

Minus sign iconPlus sign icon
Alkion BioInnovations's official website is alkinnov.com and has social profiles on LinkedInCrunchbase.

What is Alkion BioInnovations's SIC code NAICS code?

Minus sign iconPlus sign icon
Alkion BioInnovations's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Alkion BioInnovations have currently?

Minus sign iconPlus sign icon
As of July 2026, Alkion BioInnovations has approximately 14 employees across 1 continents, including Europe. Key team members include Ceo / Co-Founder: S. B.Chief Scientific Officer: J. S.Managing Director/Cto: F. Y. P.. Explore Alkion BioInnovations's employee directory with LeadIQ.

What industry does Alkion BioInnovations belong to?

Minus sign iconPlus sign icon
Alkion BioInnovations operates in the Biotechnology Research industry.

What technology does Alkion BioInnovations use?

Minus sign iconPlus sign icon
Alkion BioInnovations's tech stack includes WordPress1&1Hammer.jsSwiperModernizrLeafletIONOSWPML.

What is Alkion BioInnovations's email format?

Minus sign iconPlus sign icon
Alkion BioInnovations's email format typically follows the pattern of First.Last@alkinnov.com. Find more Alkion BioInnovations email formats with LeadIQ.

How much funding has Alkion BioInnovations raised to date?

Minus sign iconPlus sign icon
As of July 2026, Alkion BioInnovations has raised $13M in funding. The last funding round occurred on Nov 21, 2025 for $5.3M.

When was Alkion BioInnovations founded?

Minus sign iconPlus sign icon
Alkion BioInnovations was founded in 2017.
Alkion BioInnovations logo

Alkion BioInnovations

Biotechnology ResearchÎle-de-France, France11-50 Employees

Alkion BioInnovations is a biotechnology research company based near Versailles in the Île-de-France region, focused on plant tissue propagation and bioengineering. It has developed a bioproduction platform that yields high-value ingredients—from active pharmaceutical ingredients to recombinant proteins—from plant biomass for pharmaceutical and agrifood markets. The production approach emphasizes sustainability and scalability, leveraging carbon-neutral methods and optimized bioreactors to minimize resource use.

In Europe, the company collaborates with partners to advance AI-powered robotics for an industrial in-vitro bioproduction platform. Its main initiative is the large-scale production of QS, derived from the Quillaja saponaria tree, intended to boost vaccine efficacy and expand access while preserving biodiversity; the program involves collaboration with NGOs and universities. A secondary program focuses on standardized cannabinoid APIs and extracts for therapeutic markets, supported by a French health authorities R&D license granted in 2018, alongside an agrifood biosynthesis effort for a healthy sweet protein from an exotic plant.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2017
Employees
11-50

Section iconMedia & News

Section iconFunding & Financials

  • $13M

    Alkion BioInnovations has raised a total of $13M of funding over 10 rounds. Their latest funding round was raised on Nov 21, 2025 in the amount of $5.3Mas a seed.

  • $1M

    Alkion BioInnovations's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $13M

    Alkion BioInnovations has raised a total of $13M of funding over 10 rounds. Their latest funding round was raised on Nov 21, 2025 in the amount of $5.3Mas a seed.

  • $1M

    Alkion BioInnovations's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.